North American Vaccine Inc – ‘8-K’ for 3/16/00 – EX-99.2

On:  Friday, 3/24/00   ·   For:  3/16/00   ·   Accession #:  898432-0-256   ·   File #:  1-10451

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         3     10K 
 2: EX-99.1     Miscellaneous Exhibit                                  1      7K 
 3: EX-99.2     Miscellaneous Exhibit                                  1      7K 

EX-99.2   —   Miscellaneous Exhibit

[ICON](REGISTERED)

 NORTH AMERICAN VACCINE CLARIFIES REFERENCES TO CONDITIONS

   Columbia, Maryland - March 17, 2000, North American Vaccine (AMEX: NVX)
announced today that the conditions referred to in its press release issued     
yesterday, regarding the acquisition transaction with Baxter International,     
Inc., that would not be satisfied by April 1, 2000 are, obtaining regulatory    
approval from British Health authorities for NeisVac-C(TRADEMARK) vaccine and   
the manufacture of a two month supply of doses of NeisVac-C(TRADEMARK) vaccine  
for delivery under the supply agreement with British Health authorities.        
Although these conditions will not be satisfied by April 1, 2000, the company   
expects to obtain British regulatory approval and to manufacture a satisfactory 
number of doses of NeisVac-C(TRADEMARK) vaccine in due course. There can be no  
assurance that the company and Baxter will be able to negotiate a satisfactory  
modification to the Share Exchange Agreement even if the company eventually     
obtains British regulatory approval and manufactures a satisfactory number of   
doses of NeisVac-C(TRADEMARK) vaccine.                                          

 North American Vaccine, Inc. is engaged in the research, development,
production and sales of vaccines for the prevention of human infectious         
diseases. North American Vaccine news releases are available on the Company's   
web site at http://www.nava.com.                                                

     THIS PRESS RELEASE CONTAINS CERTAIN FORWARD LOOKING STATEMENTS, WHICH ARE
MADE PURSUANT TO THE SAFE HARBOR PROVISIONS OF THE SECURITIES LITIGATION REFORM 
ACT OF 1995, INCLUDING PROSPECTS FOR MEETING TERMS OF THE SHARE EXCHANGE        
AGREEMENT WITH BAXTER AND PROSPECTS FOR OBTAINING REGULATORY APPROVAL AND       
MANUFACTURING A SATISFACTORY NUMBER OF DOSES OF NEISVAC-C(TM) VACCINE. INVESTORS
ARE CAUTIONED THAT FORWARD LOOKING STATEMENTS INVOLVE RISKS AND UNCERTAINTIES   
THAT MAY AFFECT THE COMPANY'S BUSINESS AND PROSPECTS, ALL AS DISCUSSED IN THE   
COMPANY'S FILINGS WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION, INCLUDING   
ITS ANNUAL REPORTS ON FORM 10-K, QUARTERLY REPORTS ON FORM 10-Q AND CURRENT     
REPORTS ON FORM 8-K.                                                            

Dates Referenced Herein

This ‘8-K’ Filing		Date		Other Filings
		4/1/00		None on these Dates
Filed on:		3/24/00
		3/17/00
For Period End:		3/16/00
				List all Filings